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PredictorsAbstract Background and Objective: Chronic obstructive pulmonary disease (COPD) is a leading
and increasing cause of worldwide morbidity and mortality. No universal predictor of mortality and
outcome was deﬁned especially in intensive care unit (ICU)-admitted patients with acute exacerba-
tion of COPD (AECOPD). The objective was to detect the possible role of C-reactive protein (CRP)
and interleukin-6 (IL-6) levels in predicting the prognosis of ICU-admitted patients with AECOPD.
Methods: This prospective cohort study enrolled 50 adult patients with AECOPD who were
admitted in the ICU. Serum CRP and IL-6 levels were measured on admission. The primary end-
point was any-cause mortality during ICU stay or 28 days after discharge. Lengths of ICU and hos-
pital stay besides complications encountered were recorded.
Results: Serum CRP level was signiﬁcantly elevated in patients with prolonged mechanical ven-
tilation (MV) days, ICU stay and hospital stay (r= 0.406, p= 0.007; r= 0.411, p= 0.006;
r= 0.387, p= 0.010, respectively). Similar results were noted for serum IL-6 level (r= 0.554,
p=<0.001; r= 0.533, p=<0.001; r= 0.508, p= 0.001, respectively). Combined CRP and IL-6
serum levels predicted 28 day mortality at a cut-off value of 110 mg/dl and 347.8 pg/ml respectively
(AUC= 0.851, p= 0.006) with 83.33% sensitivity, 75.68% speciﬁcity, 35.71% PPV and 96.55%
NPV. This was signiﬁcantly greater than that for CRP alone (p= 0.040) or IL-6 alone (p= 0.004).
830 T.A. Helmy et al.Conclusions: Serum levels of CRP and IL-6 (either individually or combined) were useful mark-
ers in predicting the mortality, complications and outcome in ICU-admitted patients with
AECOPD.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Recently, chronic obstructive pulmonary disease (COPD) has
gained interest as a major public health concern and is cur-
rently the focus of intense research because of its persistently
increasing prevalence, mortality, and disease burden [1].
Patients with COPD have an ongoing systemic inﬂammation.
In addition, it is believed that many of the systemic manifesta-
tions of COPD are mediated through increased systemic levels
of inﬂammatory proteins such as interleukin-6 (IL-6), tumor
necrosis factor-a (TNF-a) and C-reactive protein (CRP) [2].
It is obvious that there is a great debate about the possible
role of CRP & IL-6 levels in predicting the prognosis of Inten-
sive care unit (ICU)-admitted patients with acute exacerbation
of COPD (AECOPD). The aim of this work was to detect the
possible role of CRP & IL-6 levels in predicting the prognosis
of ICU-admitted patients with AECOPD.
Subjects and methods
This prospective cohort study was conducted on 50 adult
patients of both sexes admitted to the ICUs of Alexandria
Main University Hospital or private hospitals in the governor-
ate of Alexandria. To be eligible for the study, patients were
admitted on the basis of having AECOPD which was deﬁned
as acute change in the patients’ base line dyspnea, cough,
and/or sputum production severe enough to be referred to hos-
pital and admitted to ICU for oxygen therapy, ventilatory sup-
port, hemodynamic instability or failure to improve after
empiric treatment before ICU admission. COPD patients were
deﬁned according to Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [3,4].
Patients were excluded from the study if they had bronchial
asthma, cystic ﬁbrosis or manifest immunosuppression, new
inﬁltration in chest X-ray on admission, vasculitis or other
causes that increase CRP. Patients with left heart failure or
ischemic heart disease were also excluded.
Informed consent was taken from all patients or their next
of kin. The study was approved from the ethics committee of
the Alexandria Faculty of Medicine.
Data collected
All patients included in the study were subjected to the follow-
ings: full history taking, complete clinical examination, Chest
X-ray, routine laboratory investigations and culture of spu-
tum, tracheal aspirate or bronchial lavage (when indicated).
Determination of plasma IL-6 concentration by enzyme
linked immunosorbent assay (ELISA) (ImmunoLeader,
Orgenium Kits) and determination of CRP concentration by
enzyme linked immunosorbent assay (ELISA) (ImmunoLeader),
were routinely assessed in all the studied subjects on
admission.Five ml of venous blood was withdrawn from every patient
on admission to the ICU and collected on 5% ethylenedi-
aminetetraacetic acid (EDTA). Centrifugation at 400 x g for
30 minutes was done. Plasma samples were collected and
stored in dry plastic tubes at 20 C for determination of
IL-6 concentrations.
Assay principle
Boster’s human IL-6 ELISA Kit was based on standard sand-
wich enzyme immunoassay assay technology. Standards and
samples were pipetted into wells and any IL-6 was bounded
by an immobilized antibody. Then IL6-speciﬁc enzyme linked
monoclonal antibody was added and followed by a substrate.
A color developed in proportion to the concentration of IL-6.
Subsequently, color development was stopped and its intensity
was measured.
A standard curve was drawn by the ELISA reader where
the absorbance value for each standard was plotted on the ver-
tical axis against the corresponding standard concentration
(pg/ml) on the horizontal axis of ELISA paper. Sample con-
centrations were read as pg/ml from the standard curve by
the ELISA reader using the absorbance value for each sample.
Outcome measures
The outcome of the studied cases and their complications were
traced during follow-up which included duration of ICU stay,
hospitalization and mortality within 28 days post discharge
from hospital. The end point was ‘‘adverse outcome’’, deﬁned
as the presence of at least one of the followings: Death from
any cause in the ICU or hospital, death within the 28 days per-
iod following discharge and development of acute heart failure
(this was identiﬁed clinically).
Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0 [5,6]. Qualitative data were
described using number and percent. Quantitative data were
described using Range (minimum and maximum) mean, stan-
dard deviation and median. The distributions of quantitative
variables were tested for normality using Kolmogorov–Smir-
nov test, Shapiro–Wilk test and D’Agstino test, also Histo-
gram and QQ plot were used for vision test. If it revealed
normal data distribution, parametric tests were applied. If
the data were abnormally distributed, non-parametric tests
were used. For abnormally distributed data, comparison
between two studied groups was done using Mann–Whitney
test.
Correlations between two quantitative variables were
assessed using Spearman coefﬁcient. Agreement of the differ-
ent predictives with the outcome was used and was expressed
Table 2 Distribution of the studied cases according to some
laboratory investigations.
Min.–Max. Mean ± SD Median
pH 7.0–7.32 7.23 ± 0.08 7.25
PaCO2 (mm Hg) 64.0–154.0 91.06 ± 22.37 85.50
PaO2 (mm Hg) 40.0–130.0 66.40 ± 17.89 62.50
HCO3 (m Eq/l) 23.0–46.0 36.79 ± 4.07 37.0
SaO2 (%) 58.0–99.0 90.41 ± 7.07 91.0
WBCs (c/mm3) 4000–22000 9040 ± 3.20 8400
CRP (mg/dl) 42.0–184.0 97.55 ± 32.53 89.60
IL-6 (pg/ml) 193.20–634.0 337.24 ± 98.66 322.70
CRP= C-reactive protein, IL-6 = Interleukin 6, PaCO2 = partial
pressure of arterial carbon dioxide, PaO2= partial pressure of
arterial oxygen, SaO2 = arterial oxygen saturation; WBCs = white
blood cells.
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dictive value and accuracy. Receiver operating characteristic
curve (ROC) was plotted to analyze a recommended cutoff,
the area under the ROC curve denotes the diagnostic perfor-
mance of the test. Area more than 50% gives acceptable per-
formance and area about 100% is the best performance for
the test. Signiﬁcance test results are quoted as two-tailed prob-
abilities. Signiﬁcance of the obtained results was judged at the
5% level.
Results
Demographic and clinical data
The demographic data of the study population are shown in
Table 1 where the age of the studied patients ranged from 44
to 88 years old with a mean of 63.0 ± 8.70 years. It was
noticed that there were 2 females in the studied cases and this
is well understood due to religious and traditional causes
related to smoking as a habit in our country.
As regards the patients’ symptoms on admission, all
(100%) the patients suffered from two of the cardinal symp-
toms (Cough and Dyspnea), while only 41 patients (82%)
had purulent sputum (change in the color of the sputum),
and 47 patients (94%) complained of increase in the amount
of the sputum.
Arterial gasometry, complete blood count, serum CRP and
serum IL-6 were recorded for all patients as shown in Table 2.
Notably, serum CRP and IL-6 levels increased in all patients
included.
The respiratory support management
As regards the respiratory support management of the studied
patients after excluding the 7 discharged against medical
advice (DAMA) patients, only 3 of the patients (7%) were
improved on bronchodilators and oxygen therapy only with-
out needing positive ventilation support, while 40 patients
(93%) needed noninvasive mechanical ventilation (NIMV)
for a period ranging from 1 h to 13 days with a mean of
2.70 ± 2.53 days, noticing that one patient was put on failed
NIMV trial only for one hour after which he was put on
IMV. Furthermore, some of patients were discharged on either
home Continuous positive airway pressure (CPAP) (3 patientsTable 1 Demographic and clinical data.
Min–Max. Mean ± SD Median
Age (years) 44–88 63 ± 87 63
Sex 48 (Males) 2 (females)
Annual Exacerbations 0.0–7.0 2.86 ± 1.55 3.0
Previous hospitalization 0.0–7.0 2.64 ± 1.47 2.5
Previous ICU admissions 0.0–6.0 1.98 ± 1.13 2.0
Previous MV 0.0–6.0 1.98 ± 1.17 2.0
GCS 10–15 13.52 ± 1.31 14
Duration of NIMV (days) 1 h–13 d 2.70 ± 2.53 2
Duration of IMV (days) 2 h–19 d 5.20 ± 5.53 3
GCS = Glasgow coma scale, IMV= Invasive mechanical venti-
lation, MV=Mechanical ventilation, NIMV=Noninvasive
mechanical ventilation.on their preadmission devices and 5 patients were advised to
use on discharge), or home Biphasic positive airway pressure
(BIPAP) (1 patient on his preadmission device and another
one was advised to use on discharge).
From all the studied patients after excluding the DAMA
patients, 25 patients (58.1%) needed invasive mechanical ven-
tilation (IMV) either from the start or after failed trial of
NIMV; with a period ranged from 2 h to 19 days with a mean
value of 5.20 ± 5.53 days, noticing that one patient was put on
IMV for 2 h but self extubation happened and the patient was
put on NIMV completing the course of treatment without
needing further IMV.
The outcome measures
Regarding the outcome of the studied patients according to
MV days, ICU stay and hospital stay as shown in Table 3,
MV days ranged from 10 h to 20 days with a mean value of
5.53 ± 4.88 days, noticing that the duration of MV was con-
sidered as the total MV period during hospitalization either
NIMV or IMV or both, with one patient was put on NIMV
only for 10 h after which he did not need further positive pres-
sure ventilation. While the ICU stay period ranged from 2 to
23 days with a mean value of 7.07 ± 4.73 days. And the hospi-
tal stay period ranged from 3 days to 27 days with a mean
value of 9.44 ± 5.86 days.
According to the discharge type as shown in Table 4, 7
patients (14%) were DAMA, 38 patients (76%) were dis-
charged after improvement, and 5 patients (10%) unfortu-
nately died. Six patients (14%) died within the 28 days post
discharge; and 6 patients (14%) suffered from acute heart
failure.Table 3 Distribution of the studied cases according to MV,
ICU stay and hospital stay.
Min.–Max. Mean ± SD Median
MV* days 10 h–20 d 5.53 ± 4.88 4.0
ICU stay 2.0–23.0 7.07 ± 4.73 6.0
Hospital stay 3.0–27.0 9.44 ± 5.86 8.0
* MV days are the total mechanical ventilation period during
hospitalization either noninvasive or invasive or both.
Table 4 Distribution of the studied cases according to the
outcome measures.
No %




28 day mortality (n = 43)
Survival 37 86.0
Death 6 14.0
Acute heart failure (n = 43)
No 37 86.0
Yes 6 14.0
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Correlating serum CRP level to MV days, ICU stay and hos-
pital stay as shown in Table 5, it was noticed that the serum
CRP level was signiﬁcantly elevated in relation to increase of
the period of MV days (r= 0.406, p= 0.007), ICU stay
(r= 0.411, p= 0.006) and hospital stay (r= 0.387,
p= 0.010), but it was insigniﬁcant in relation to NIMV days
(r= 0.089, p= 0.569), although it was found signiﬁcant in
relation to IMV days (r= 0.452, p= 0.002).
The same results were noted for IL-6 as shown in Table 5. It
was signiﬁcantly elevated in relation to increase of the period
of MV days (r= 0.554, p=< 0.001), ICU stay (r= 0.533,
p=< 0.001) and hospital stay (r= 0.508, p= 0.001), but it
was insigniﬁcant in relation to NIMV days (r= 0.147,
p= 0.346), although it was found signiﬁcant in relation to
IMV days (r= 0.478, p= 0.001).
For the relation between the discharge type and serum CRP
and IL-6 levels, the mean value of CRP in sera of the improved
patients was 96.12 ± 31.59 ranging from 42 to 174 mg/dl,
while in the dead patients it was 115.88 ± 25.70 mg/dl ranging
from 86 to 147 mg/dl. Although CRP level was elevated in
both types of patients on admission, it lacked signiﬁcance in
relation to improvement or death of these patients with a p
value of 0.134. Nevertheless, the mean value of IL-6 in sera
of the improved patients was 322.15 ± 91.79 pg/ml ranging
from 193 to 634 pg/ml. In the dead patients, it was
415.32 ± 98.53 pg/ml ranging from 347.4 to 584.4 pg/ml.
The latter relation was proved signiﬁcant (p= 0.019).Table 5 Correlation between CRP and IL-6 with MV, ICU
stay and hospital stay.
CRP IL-6
rs p rs p
MV days 0.406* 0.007 0.554* <0.001
ICU stay 0.411* 0.006 0.533* <0.001
Hospital stay 0.387* 0.010 0.508* 0.001
Duration of NIMV 0.089 0.569 0.147 0.346
Duration of IMV 0.452* 0.002 0.478* 0.001
rs: Spearman coefﬁcient.
CRP= C-reactive protein, IL-6 = Interleukin 6, IMV=Nonin-
vasive mechanical ventilation, MV=Mechanical ventilation,
NIMV=Noninvasive mechanical ventilation.
* Statistically signiﬁcant at p 6 0.05.Concerning the relation between serum CRP on admission
and 28 day mortality, in survived patients, serum CRP ranged
from 42 to 174 mg/dl with a mean value of 94.47 ± 30.33 mg/
dl. The mean serum CRP value in dead patients was
122.73 ± 28.46 mg/dl ranging from 86 to 157 mg/dl. Therefore,
there was a signiﬁcant relation between serum CRP on admis-
sion and 28 day mortality (p= 0.040). Similar results were
noted for serum IL-6, ranging from 193.20 to 526.40 pg/ml in
survived patients with a mean value of 313.72 ± 76.72 pg/ml
while in passed patients it ranged from 347.40 to 634.0 pg/ml
with a mean value of 451.77 ± 125.45 pg/ml. There was a sig-
niﬁcant relation between 28 day mortality and serum IL-6 on
admission (p= 0.004).
In the current study, about 6 patients developed acute heart
failure following the pre-deﬁned inclusion criteria. Serum CRP
and IL-6 levels in those patients on admission revealed a mean
value of 96.0 ± 20.33 and 276.57 ± 57.93 pg/ml, respectively.
The relation between serum CRP and IL-6 levels and develop-
ment of acute heart failure lacked signiﬁcance. (p= 0.987 and
p= 0.061, respectively).
ROC curve for combined results of CRP and IL-6 with
28 day mortality rate revealed a cut off value for CRP of
110 mg/dl and for IL-6 of 347.8 pg/ml with sensitivity of
83.33%, speciﬁcity of 75.68%, positive predictive value
(PPV) of 35.71% and negative predictive value (NPV) of
96.55% (Fig. 1). The area under the curve (AUC) was 0.851
with p= 0.006 which is signiﬁcantly greater than that for
CRP (p= 0.040) or IL-6 (p= 0.004) on an individual basis
with a magnitude considered to be clinically useful, and
76.74% accuracy in predicting the above mentioned outcome.
Discussion
The levels of many cytokines are known to be raised in sera of
COPD patients. Frequent exacerbations are associated with
increased pulmonary and systemic inﬂammation, and IL-6 isFigure 1 Receiver operating characteristic (ROC) curve for
CRP, IL-6 with 28 day mortality. AUC= Area under the curve,
*Statistically signiﬁcant at p 6 0.05.
Role of C-reactive protein and interleukin-6 833a systemic inﬂammation marker suggested to be increased dur-
ing exacerbations [7]. The growing literature is suggesting that
CRP may be a useful systemic biomarker of lung inﬂamma-
tion. Furthermore, CRP is easily measured, in comparison to
exhaled or more exotic biomarkers [8].
To the best of our knowledge, this has been the ﬁrst study
prospectively conducted on patients who had been admitted to
the ICU with AECOPD to evaluate the prognostic value of
combined CRP and IL-6 in ICU according to the mentioned
outcome parameters.
Akbulut et al. [7] evaluated IL-6 and IL-8 levels in patients
with AECOPD and Wedzicha et al. [9] both showed a signiﬁ-
cant elevation in serum IL-6 levels on admission of patients
with AECOPD. Moreover, in one study that evaluated sys-
temic cytokine proﬁle of patients hospitalized during an
AECOPD, Malo et al. [10] documented a signiﬁcant increase
in IL-6 and CRP levels on hospital admission. This was
evident in high mean CRP and IL-6 levels in sera of our stud-
ied patients (97.55 ± 32.53 mg/dl and 337.24 ± 98.66 pg/ml,
respectively).
Wide variety of inﬂammatory mediators have been shown
to be increased in COPD patients, attract inﬂammatory cells
from the circulation (chemotactic factors), amplify the inﬂam-
matory process (proinﬂammatory cytokines), and induce
structural changes. [3].
Ucgun et al. [11] found that the length of ICU stay was
7.1 ± 5.5 days in survivors (n= 101) and was 6.3 ± 5.1 days
in non-survivors (n= 50), and the length of hospital stay
was 11.9 ± 8.2 days in survivors and was 7.3 ± 5.7 days in
non-survivors, while Nevins et al. [12] reported that the mean
duration of MV was 8.9 days (median 4.1 days).
Our ﬁndings suggest that the serum CRP level was signiﬁ-
cantly elevated in relation to increased period of MV days
(r= 0.406, p= 0.007), ICU stay (r= 0.411, p= 0.006) and
hospital stay (r= 0.387, p= 0.010), but it was noticed to be
insigniﬁcant in relation to NIMV days (r= 0.089,
p= 0.569), although it was noticed to be signiﬁcant in relation
to IMV days (r= 0.452, p= 0.002).
Similar to our results, Ucgun et al. [11] studied the predic-
tors of hospital outcome and intubation in COPD patients
admitted to the respiratory ICU for acute hypercapnic respira-
tory failure as they reported that the serum CRP levels on
admission in their patients (87 patients) were found to be sta-
tistically signiﬁcant in relation to length of ICU stay (days)
(p= 0.01) and length of hospital stay (days) (p< 0.001),
and they found that the serum CRP levels on admission were
signiﬁcantly elevated in patients who needed invasive mechan-
ical ventilation(p= 0.001).
Stolz et al. [13] studied Copeptin, CRP, and Procalcitonin
as prognostic biomarkers in AECOPD. They found that
CRP levels correlated neither with the length of hospital stay
(p 0.714) nor the length of ICU stay (p= 0.835). Levels in
those requiring ICU care were similar to those treated on the
ward (p= 0.931). A comparison of clinical outcomes in
patients with CRP levels <50 mg/L and >50 mg/L on ICU
admission in their study was done. The length of hospital stay
did not differ in these two groups of patients (p= 0.417). Lev-
els in survivors and nonsurvivors were similar (p= 0.129).
Different results can be explained by different durations of
follow up. We studied the short term outcome (15 and 28 mor-
tality rates), while Stolz et al. [13] followed their patients for a
longer duration (6 months), they found that CRP levels weresigniﬁcantly elevated at the exacerbation and decreased sub-
stantially thereafter, with comparable levels after 14 days and
6 months. However, CRP levels on hospital admission are
not correlated to long-term outcome of the exacerbation, as
CRP levels rise rapidly during infection or after injury, to just
decline after the initial stimulus has vanished. Moreover, CRP
fails to provide any further information about prognosis in the
acute event due to its high sensitivity but low speciﬁcity [14].
In the current study, regarding the correlation between Il-6
and MV, ICU stay and hospital stay, it was noticed that IL-6
was signiﬁcantly elevated in relation to increase of the period
of MV days (r= 0.554, p=< 0.001), ICU stay (r= 0.533,
p=< 0.001) and hospital stay (r= 0.508, p= 0.001). Never-
theless, it was noted to be insigniﬁcant in relation to NIMV
days (r= 0.147, p= 0.346) and proved signiﬁcant in relation
to IMV days (r= 0.478, p= 0.001).
Bayir et al. [15] evaluated the relation between mortality
rate, duration of hospitalization and levels of CRP, TNFa,
IL-6 and catalase on admission for patients with AECOPD
presented to the emergency department. They found that the
mean values of leukocytic count, sedimentation rate, CRP
and IL-6 in dead patients were signiﬁcantly higher than those
in the discharged patients (p= 0.040, 0.038, 0.02, 0.017,
respectively). High CRP and IL-6 values in sera of patients
with AECOPD presenting to the emergency department may
indicate the requirement of ICU admission and treatment with
mechanical ventilation, and a high mortality.
Noted in the current study, the mean value of CRP in sera
of the improved patients was 96.12 ± 31.59 mg/dl ranging
from 42 to 174 mg/dl. In the dead patients it was
115.88 ± 25.70 mg/dl ranging from 86 to 147 mg/dl. Despite
this apparent difference between survivors and non-survivors,
it lacks signiﬁcance in relation to improvement or death of our
patients (p= 0.134).
Bakr et al. [16], in a cohort of 220 patients with acute respi-
ratory failure (ARF) secondary to COPD, requiring mechani-
cal ventilation (MV) and admitted to the ICU over a two-year
period concluded that CRP level differed insigniﬁcantly
between survivors and non-survivors.
Concerning the mean value of IL-6 in sera of the improved
patients, it was 322.15 ± 91.79 pg/ml ranging from 193 to
634 pg/ml. In the dead patients, it was 415.32 ± 98.53 pg/ml
ranging from 347.4 to 584.4 pg/ml, which was found to be sig-
niﬁcantly high with p value of 0.019.
On studying the relation between serum CRP and IL-6 lev-
els of the studied patients on admission and mortality, both
were found signiﬁcant in 28 day mortality. (p= 0.040 and
p= 0.004, respectively). These results were similar to those
of Dahl et al. [17] who studied CRP as a predictor of prognosis
in COPD and concluded that increased serum CRP may also
increase the risk of all-cause mortality in individuals with pul-
monary dysfunction and CRP is a strong long-term predictor
of COPD hospitalization and death, independent of smoking
and lung function.
In our study, about 6 patients developed acute heart failure
following the pre-deﬁned inclusion criteria. In relation to the
value of serum CRP and IL-6 levels on admission, both were
found insigniﬁcant regarding the patients who did not develop
acute heart failure at the end of the study. (p= 0.987 and
p= 0.061, respectively).
Compared to our results, Wedzicha et al. [9] found
that AECOPD was accompanied by elevations of plasma
834 T.A. Helmy et al.ﬁbrinogen and serum IL-6 levels. Transient acute increase in
plasma ﬁbrinogen was found to be an independent risk factor
for congestive heart disease and COPD exacerbation (medi-
ated through a rise in IL-6). Thus, providing a mechanism
linking respiratory inﬂammation to risk of coronary heart
disease.
Concerning the ROC curve for applying both biomarkers
(CRP & IL-6) as predictors of 28 day mortality, the cutoff
CRP value raised to 110 mg/dl and IL-6 raised to 347.8 pg/
ml (compared to each biomarker alone) with notable change
in sensitivity from 66.67% to 100% for individual CRP and
IL-6 levels respectively to 83.33% combined and notable
change in speciﬁcity from 78.38% to 72.97% for individual
CRP and IL-6 levels respectively to 75.68% combined. PPV
for both biomarkers combined was 35.71% which was slightly
more than that of CRP alone (33.33%) or near that of IL-6
alone (37.50%). NPV was changed to 96.55% and the AUC
was 0.851 with p= 0.006 which is signiﬁcantly greater than
that of CRP alone (p= 0.040) while it was near that of IL-6
with AUC= 0.874 (p= 0.004) with magnitude to be consid-
ered clinically with 76.74% accuracy in predicting the above
mentioned outcome.
These results go with those of Hurst et al. [18] who studied
the use of plasma biomarkers at exacerbation of COPD. They
found that CRP cutoff value at 5 mg/L would be 74.4% sensi-
tive and 57.5% speciﬁc for conﬁrmation of exacerbation.
There was a signiﬁcant correlation between plasma IL-6 and
CRP concentrations (r= 0.60, p= 0.001), the increase in
IL-6 remained signiﬁcantly associated with the increase in
CRP (r= 0.63, p= 0.0001).
CRP is an acute phase protein produced by the liver in
response to IL-6 stimulation [19]. CRP is raised in most condi-
tions associated with infection, inﬂammation or tissue damage,
for which it is a sensitive marker [19]. Evidence suggests that
CRP and IL-6 may also be implicated in the pathophysiology
of COPD [18].
Comparing the results of the current study with the previ-
ously mentioned studies shows a low PPV of the levels of
CRP and IL-6 on admission of ICU patients with acute exac-
erbation of COPD in contrast to its high NPV. Moreover, the
rising levels of our studied biomarkers (CRP and IL-6) were
considered to have a high sensitivity but low speciﬁcity in pre-
dicting the outcome. Nevertheless, the speciﬁcity was raised
when using the combined relation between CRP, IL-6 and out-
come measures. This can be interpreted as these cytokines are
related to the clinical and prognostic parameters and can be
useful for evaluation of the therapy instituted for the disease.
Finally, interrelationships between biomarkers at exacerbation
suggest that monocytic pathways may be an important target
for future research [18].
The followings are limitations of our study: a relatively low
number of patients, a relatively delayed onset of NIV applica-
tions in ER, inclusion of not only patients with uncomplicated
AECOPD but also those with other comorbid diseases (malig-
nancy, renal failure and sepsis), our study was not speciﬁcally
designed to differentiate the role of bacterial or viral infection
in the pathogenesis of the exacerbation, failure to follow the
DAMA patients and the short period of follow up.
In conclusion CRP and IL-6 as biological markers were
noticed to be elevated in patients with AECOPD who needed
ICU admission. CRP and IL-6 are good indicators of future
increase of MV days, hospital stay and ICU stay. There was asigniﬁcant relation between CRP and IL-6 levels and mortality.
There was no signiﬁcant relation between CRP and IL-6 levels
and development of acute heart failure regarding the inclusion
criteria in the study. The use of cutoff value may be chosen to
maximize sensitivity and speciﬁcity, as required. CRP was
found to be sensitive but not sufﬁciently speciﬁc with low
NPV and high PPV in predicting the outcome. IL-6 was found
to be sensitive but more speciﬁc than CRP with low NPV and
high PPV in predicting the outcome. The use of combined
CRP and IL-6 levels in predicting the outcome had improved
the speciﬁcity but the sensitivity was decreased. From the cur-
rent study, it was noticed that the serum CRP and serum IL-6
levels in sera of patients with AECOPD who needed ICU
admission, measured on admission, may provide a useful means
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